◌
Adaptive Bioelectronics
Functional interaction, peripheral interfaces and selective bioelectronic intervention.
Aurealix
Adaptive Bioelectronic and Biopharmaceutical Technologies.
Research architecture. Experimental validation. Translation.
Aurealix develops research architectures, experimental technologies and validation infrastructure for adaptive interaction with complex physiological systems.
◎
Proteostasis
Biological-state dynamics, longitudinal recovery and probabilistic intervention.
↗
Research Platform
Governed infrastructure for reproducible, prospective experimental research.
✓
Validation
Two independent initial tracks designed to build evidence before translation.
Research programme
Two domains. One evidence-driven approach.
Aurealix combines adaptive bioelectronics with biopharmaceutical and proteostasis research while keeping their initial validation pathways independent.
The longer-term question of convergence remains a research direction, not a prerequisite for either programme.
Track A
Adaptive Bioelectronics.
Experimental investigation of peripheral bioelectronic interaction, functional mapping, prospective prediction and selective intervention.
Potential future applications include assistive neurotechnology, neuroprosthetic interfaces, selective neuromodulation and pain modulation.
Track B
Probabilistic Intervention & Proteostasis.
Experimental investigation of bounded probabilistic intervention alongside longitudinal biological-state and recovery dynamics.
Application-specific and clinical translation follow only where experimental evidence supports progression.
Scientific architecture
Complementary frameworks. Distinct research questions.
The Aurealix Architecture separates scientific frameworks from specific devices, algorithms and patent-protected implementations.
Aurealix Research Platform
From architecture to reproducible evidence.
ARP is a governed experimental research environment supporting configuration, evidence capture, prospective validation, provenance and longitudinal research.
Intellectual property
Selective protection alongside validation.
Aurealix develops and evaluates intellectual property selectively across adaptive bioelectronics, probabilistic intervention, biological-state research and enabling technologies. Public descriptions remain deliberately distinct from protected implementation detail.
Direction
Research architecture → experimental validation → application validation → clinical translation.
Research Brief
Issue 01 | 2026
A concise public overview of Aurealix research architectures, research software, technical selection and the transition toward two independent experimental validation tracks.